Institute of Clinical and Translational Research, Biomedical Research Center SAS, Bratislava, Slovakia.
Cancer Research Institute, Biomedical Research Center SAS, Bratislava, Slovakia.
Biochem Pharmacol. 2020 Jan;171:113695. doi: 10.1016/j.bcp.2019.113695. Epub 2019 Nov 9.
Several papers have reported that calcium channel blocking drugs were associated with increased breast cancer risk and worsened prognosis. One of the most common signs of breast tumors is the presence of small deposits of calcium, known as microcalcifications. Therefore, we studied the effect of dihydropyridine nifedipine on selected calcium transport systems in MDA-MB-231 cells, originating from triple negative breast tumor and JIMT1 cells that represent a model of HER2-positive breast cancer, which possesses amplification of HER2 receptor, but cells do not response to HER2 inhibition treatment with trastuzumab. Also, we compared the effect of nifedipine on colorectal DLD1 and ovarian A2780 cancer cells. Both, inositol 1,4,5-trisphosphate receptor type 1 (IPR1) and type 1 sodium calcium exchanger (NCX1) were upregulated due to nifedipine in DLD1 and A2780 cells, but not in breast cancer MDA-MB-231 and JIMT1 cells. On contrary to MDA-MB-231 and JIMT1 cells, in DLD1 and A2780 cells nifedipine induced apoptosis in a concentration-dependent manner. After NCX1 silencing and subsequent treatment with nifedipine, proliferation was decreased in MDA-MB-231, increased in DLD1 cells, and not changed in JIMT1 cells. Silencing of IPR1 revealed increase in proliferation in DLD1 and JIMT1 cells, but caused decrease in proliferation in MDA-MB-231 cell line after nifedipine treatment. Interestingly, after nifedipine treatment migration was not significantly affected in any of tested cell lines after NCX1 silencing. Due to IPR1 silencing, significant decrease in migration occurred in MDA-MB-231 cells after nifedipine treatment, but not in other tested cells. These results support different function of the NCX1 and IPR1 in the invasiveness of various cancer cells due to nifedipine treatment.
已有多篇文献报道钙通道阻滞剂与乳腺癌风险增加和预后恶化相关。乳腺肿瘤的最常见迹象之一是存在钙的小沉积,称为微钙化。因此,我们研究了二氢吡啶硝苯地平对源自三阴性乳腺癌的 MDA-MB-231 细胞和代表 HER2 阳性乳腺癌模型的 JIMT1 细胞中选定钙转运系统的影响,HER2 受体扩增,但细胞对曲妥珠单抗的 HER2 抑制治疗无反应。此外,我们比较了硝苯地平对结直肠 DLD1 和卵巢 A2780 癌细胞的影响。二氢吡啶地平在 DLD1 和 A2780 细胞中均上调了肌醇 1,4,5-三磷酸受体 1 (IPR1) 和 1 型钠钙交换器 (NCX1),但在乳腺癌 MDA-MB-231 和 JIMT1 细胞中则没有。与 MDA-MB-231 和 JIMT1 细胞相反,硝苯地平在 DLD1 和 A2780 细胞中以浓度依赖的方式诱导细胞凋亡。NCX1 沉默后,用硝苯地平处理,MDA-MB-231 细胞增殖减少,DLD1 细胞增殖增加,JIMT1 细胞增殖不变。IPR1 沉默显示 DLD1 和 JIMT1 细胞的增殖增加,但硝苯地平处理后 MDA-MB-231 细胞的增殖减少。有趣的是,NCX1 沉默后,硝苯地平处理后,在任何测试的细胞系中迁移均无明显变化。由于 IPR1 沉默,硝苯地平处理后 MDA-MB-231 细胞的迁移显著减少,但在其他测试细胞中则没有。这些结果支持硝苯地平处理后不同的 NCX1 和 IPR1 在各种癌细胞侵袭性中的不同功能。